DPP4 inhibitors, such as sitagliptin, linagliptin, vildagliptin, and saxagliptin, have good efficacy, safety and tolerability in the treatment of type II diabetes (48). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.